A Phase 2 interventional study of BI 456906 and Placebo in Obesity, sponsored by Boehringer Ingelheim. Completed at 43 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-02.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.
Among the 22 studies testing survodutide in Obesity, this one is the 6th largest by enrollment, is the only one that started in 2021, is the only one in phase 2, and was the 2nd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Germany
Ages 18–65 · Healthy volunteers
Boehringer Ingelheim · Sites in United States, China, Germany and 2 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, United Kingdom
Ages 45–65 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2021.
This study's enrollment of 387 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 121 across the 22 interventional studies. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 1 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
32 studies in Obesity by Boehringer Ingelheim: 5 open now, 11 under way, 3 of them phase 3. Of 21 finished, 4 (19%) have results posted.
Among the 32 studies in Obesity by Boehringer Ingelheim, this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 2, and was the 7th registered.
Boehringer Ingelheim’s Obesity studies by the year they started, since 2005.
3 of the studies testing survodutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07768813Boehringer IngelheimA Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity | 2026-12-08 |
| NCT05202353Boehringer IngelheimA Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver | 2027-01-06 |
| NCT07940244Boehringer IngelheimA Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing survodutide in Obesity, from their registry updates:
Among Boehringer Ingelheim’s 32 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight.
Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin once a week. Placebo injections look like BI 456906 injections but do not contain any medicine.
Participants are in the study for about a year. During this time, there are about 20 in-person visits to the study site. At the study site visits, doctors measure participants' body weight. Results are compared between the BI 456906 groups and the placebo group. The doctors also regularly check the general health of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BI 456906
Drug: Placebo
Drug: BI 456906
Drug: BI 456906
Drug: BI 456906
BI 456906
Also known as: Survodutide
Placebo
Percentage Change in Body Weight From Baseline to Week 46
Percentage change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures, an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. That is, a hypothetical strategy was used for intercurrent event (ICE) "COVID-19 pandemic-related early treatment discontinuation", a treatment policy strategy for ICE "non-pandemic-related early treatment discontinuation".
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Weight Loss of ≥ 5% of Baseline Weight at Week 46
Weight loss of greater than or equal to 5 percent (≥5%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥5% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
Time frame: At baseline and at Week 46.
Weight Loss of ≥ 10% of Baseline Weight at Week 46
Weight loss of greater than or equal to 10 percent (≥10%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥10% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
Time frame: At baseline and at Week 46.
Weight Loss of ≥ 15% of Baseline Weight at Week 46
Weight loss of greater than or equal to 15 percent (≥15%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥15% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
Time frame: At baseline and at Week 46.
Absolute Change in Body Weight From Baseline to Week 46
Absolute change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Absolute Change in Waist Circumference From Baseline to Week 46
Absolute change in waist circumference from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline waist circumference as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 6, 12, 18, 24, 32, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
Time frame: Baseline, Week 6, 12, 18, 24, 32, 40, and 46.
Absolute Change in Systolic Blood Pressure From Baseline to Week 46
Absolute change in systolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline systolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Absolute Change in Diastolic Blood Pressure From Baseline to Week 46
Absolute change in diastolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline diastolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
This was a randomised, double-blinded, parallel-design, placebo-controlled, multi-national, and multi-centre study with four different BI 456906 maintenance doses (ranging from 0.6 mg/week to 4.8 mg/week) in patients with obesity or overweight (body mass index (BMI) \>=27 kg/m\^2), and without diabetes mellitus.
| Milestone | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Started | 78 | 78 | 77 | 77 | 77 |
| Treated during dose escalation period | 77 | 78 | 77 | 77 | 77 |
| Completed | 55 | 60 | 59 | 55 | 57 |
| Not completed | 23 | 18 | 18 | 22 | 20 |
| Withdrew: Other not specified below | 3 | 3 | 2 | 1 | 3 |
| Withdrew: Protocol violation | 2 | 2 | 0 | 2 | 1 |
| Withdrew: Burden of study procedures | 2 | 1 | 1 | 1 | 5 |
| Withdrew: Change of residence | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Perceived lack of efficacy | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Adverse event | 9 | 10 | 12 | 17 | 3 |
| Withdrew: Adverse event: covid-infection | 4 | 1 | 2 | 1 | 0 |
| Withdrew: Not treated | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Milestone | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Started | 55 | 60 | 59 | 55 | 57 |
| Completed | 47 | 45 | 48 | 47 | 46 |
| Not completed | 8 | 15 | 11 | 8 | 11 |
| Withdrew: Perceived lack of efficacy | 0 | 2 | 1 | 0 | 1 |
| Withdrew: Adverse event | 2 | 8 | 5 | 4 | 1 |
| Withdrew: Adverse event: covid infection | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Covid-related | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Burden of study procedures | 1 | 2 | 0 | 1 | 0 |
| Withdrew: Change of residence | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Missing | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other than listed above | 2 | 0 | 3 | 2 | 6 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 1 |
Percentage change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures, an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. That is, a hypothetical strategy was used for intercurrent event (ICE) "COVID-19 pandemic-related early treatment discontinuation", a treatment policy strategy for ICE "non-pandemic-related early treatment discontinuation".
| Percentage change | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Percentage Change in Body Weight From Baseline to Week 46 | -6.19 ± 1.07 | -12.51 ± 1.01 | -13.22 ± 1.04 | -14.94 ± 1.01 | -2.82 ± 1.06 |
Weight loss of greater than or equal to 5 percent (≥5%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥5% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
| Percentage of participants | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Weight Loss of ≥ 5% of Baseline Weight at Week 46 | 60.7 | 81.0 | 82.0 | 82.8 | 25.9 |
Weight loss of greater than or equal to 10 percent (≥10%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥10% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
| Percentage of participants | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Weight Loss of ≥ 10% of Baseline Weight at Week 46 | 33.9 | 65.5 | 65.6 | 68.8 | 11.1 |
Weight loss of greater than or equal to 15 percent (≥15%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥15% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
| Percentage of particpants | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Weight Loss of ≥ 15% of Baseline Weight at Week 46 | 12.5 | 37.9 | 45.9 | 54.7 | 5.6 |
Absolute change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
| Kilogram (kg) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Absolute Change in Body Weight From Baseline to Week 46 | -7.21 ± 1.06 | -14.75 ± 1.03 | -15.64 ± 1.04 | -18.47 ± 1.04 | -2.68 ± 1.04 |
Absolute change in waist circumference from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline waist circumference as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 6, 12, 18, 24, 32, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
| Centimeter (cm) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Absolute Change in Waist Circumference From Baseline to Week 46 | -8.32 ± 1.22 | -14.99 ± 1.21 | -14.96 ± 1.19 | -16.01 ± 1.19 | -3.96 ± 1.20 |
Absolute change in systolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline systolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
| Millimeter of mercury (mmHg) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Absolute Change in Systolic Blood Pressure From Baseline to Week 46 | -6.19 ± 1.47 | -8.08 ± 1.48 | -8.66 ± 1.44 | -8.62 ± 1.46 | -2.46 ± 1.46 |
Absolute change in diastolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline diastolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
| Millimeter of mercury (mmHg) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| Absolute Change in Diastolic Blood Pressure From Baseline to Week 46 | -3.31 ± 0.90 | -4.36 ± 0.90 | -4.31 ± 0.87 | -4.80 ± 0.89 | -1.87 ± 0.89 |
Collected over From first drug administration until last drug administration, plus 28 days residual effect period (REP), up to 360 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.6 mg BI 456906 - Actual Maintenance Treatment | 0/92 (0%) | 2/92 (2.2%) | 70/92 (76.1%) |
| 2.4 mg BI 456906 - Actual Maintenance Treatment | 0/92 (0%) | 3/92 (3.3%) | 79/92 (85.9%) |
| 3.6 mg BI 456906 - Actual Maintenance Treatment | 0/71 (0%) | 4/71 (5.6%) | 64/71 (90.1%) |
| 4.8 mg BI 456906 - Actual Maintenance Treatment | 0/54 (0%) | 4/54 (7.4%) | 46/54 (85.2%) |
| Placebo | 0/77 (0%) | 5/77 (6.5%) | 48/77 (62.3%) |
| Event | 0.6 mg BI 456906 - Actual Maintenance Treatment | 2.4 mg BI 456906 - Actual Maintenance Treatment | 3.6 mg BI 456906 - Actual Maintenance Treatment | 4.8 mg BI 456906 - Actual Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| CholecystitisHepatobiliary disorders | 0/92 | 0/92 | 0/71 | 1/54 | 0/77 |
| CholelithiasisHepatobiliary disorders | 0/92 | 0/92 | 0/71 | 1/54 | 0/77 |
| TonsillitisInfections and infestations | 0/92 | 0/92 | 0/71 | 1/54 | 0/77 |
| Glioblastoma multiformeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 0/92 | 0/71 | 1/54 | 0/77 |
| Uterine prolapseReproductive system and breast disorders | 0/92 | 0/92 | 0/71 | 1/54 | 0/77 |
| Incisional herniaInjury, poisoning and procedural complications | 0/92 | 0/92 | 1/71 | 0/54 | 0/77 |
| Wrist fractureInjury, poisoning and procedural complications | 0/92 | 0/92 | 1/71 | 0/54 | 0/77 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 0/92 | 1/71 | 0/54 | 0/77 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/92 | 0/92 | 1/71 | 0/54 | 0/77 |
| COVID-19 pneumoniaInfections and infestations | 0/92 | 0/92 | 0/71 | 0/54 | 1/77 |
| Event | 0.6 mg BI 456906 - Actual Maintenance Treatment | 2.4 mg BI 456906 - Actual Maintenance Treatment | 3.6 mg BI 456906 - Actual Maintenance Treatment | 4.8 mg BI 456906 - Actual Maintenance Treatment | Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 36/92 | 60/92 | 45/71 | 32/54 | 15/77 |
| VomitingGastrointestinal disorders | 13/92 | 28/92 | 28/71 | 13/54 | 4/77 |
| ConstipationGastrointestinal disorders | 11/92 | 19/92 | 22/71 | 13/54 | 4/77 |
| DiarrhoeaGastrointestinal disorders | 22/92 | 21/92 | 17/71 | 9/54 | 8/77 |
| COVID-19Infections and infestations | 18/92 | 11/92 | 17/71 | 7/54 | 17/77 |
| Decreased appetiteMetabolism and nutrition disorders | 11/92 | 10/92 | 16/71 | 3/54 | 1/77 |
| FatigueGeneral disorders | 6/92 | 5/92 | 13/71 | 5/54 | 6/77 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/92 | 7/92 | 10/71 | 5/54 | 3/77 |
| DizzinessNervous system disorders | 1/92 | 8/92 | 10/71 | 4/54 | 2/77 |
| HeadacheNervous system disorders | 8/92 | 7/92 | 10/71 | 5/54 | 6/77 |
Full analysis set (FAS): All randomised participants who received at least one dose of trial medication and who had analysable data for at least one efficacy endpoint, using planned maintenance treatment.
| Age, Continuous(Years) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 48.6 ± 12.6 | 49.0 ± 13.1 | 50.3 ± 11.8 | 47.6 ± 13.5 | 50.0 ± 13.5 | 48.9 ± 12.8 |
| Sex: Female, Male(Participants) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 51 | 54 | 51 | 53 | 53 | 262 |
| Male | 26 | 24 | 25 | 23 | 24 | 122 |
| Ethnicity (NIH/OMB)(Participants) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 2 | 6 | 5 | 17 |
| Not Hispanic or Latino | 74 | 77 | 74 | 70 | 72 | 367 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 8 | 9 | 9 | 7 | 7 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 | 2 |
| Black or African American | 10 | 8 | 3 | 8 | 8 | 37 |
| White | 59 | 60 | 63 | 59 | 60 | 301 |
| More than one race | 0 | 1 | 1 | 0 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Body weight at baseline(Kilogram (kg)) | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 2.4 mg BI 456906 - Planned Maintenance Treatment | 3.6 mg BI 456906 - Planned Maintenance Treatment | 4.8 mg BI 456906 - Planned Maintenance Treatment | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 106.98 ± 18.71 | 106.57 ± 22.97 | 104.68 ± 19.63 | 105.86 ± 17.39 | 104.32 ± 22.95 | 105.68 ± 20.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Mar 2021 to primary completion in Sep 2022, 18 months.
Results were first posted in Nov 2023, 1 year 1 month after primary completion. A results delay was requested in Aug 2023.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 18 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Survodutide